The pharma ADMET testing market in Middle East & Africa is expected to grow from US$ 270.94 million in 2022 to US$ 437.71 million by 2028. It is estimated to grow at a CAGR of 8.3% from 2022 to 2028.

The disaster of a rising number of therapeutic molecules in the last phases of clinical trials has cost money and valuable time invested in developing new drugs. This has led to higher investments being made in the development of fresher technology for toxicity testing. According to the article “Importance of ADME/Tox in Early Drug Discovery, ” 2022, in the current drug discovery and development pipeline, only 10 molecules out of 1,000 screened hits are projected to enter the preclinical testing stage, and only 9.6% will enter clinical trials.

The drug approval process is projected to take 15 years on an average, and phases II and III are the most expensive phases of clinical trials. According to the study titled “Why 90% of Clinical Drug Development Fails and How to Improve It?”, 2022, 90% of clinical drug development fails despite implementing many strategies. After entering clinical investigations, 9 out of 10 drug candidates fail during phase I, II, and III clinical trials and the drug approval process. Drug candidates rejected in preclinical stages are not included in the 90% failure rate of the drugs in clinical stages, as they do not enter the phase I clinical trials. If preclinical drug candidates are included, the drug discovery and development failure rate rise even higher than 90%. According to analyses of clinical trial data from 2010 to 2017, lacking clinical effectiveness (40–50%), uncontrollable toxicity (30%), poor drug-like qualities (10–15%), no commercial needs, and ineffective strategic planning (10%) are the four major causes of trial failure. New drug development is both resource and time-intensive, where later clinical stages result in high costs.

To lower the attrition rate in drug research & development, it is crucial to filter and optimize the absorption, distribution, metabolism, elimination, and toxicity (ADMET) characteristics of pharmaceuticals at an early stage. It has been widely accepted that drug ADMET properties should be considered as early as possible to reduce failure rates in the clinical phase of drug discovery. In vitro and in vivo drug evaluation techniques have reached maturity in preclinical applications, and in silico technologies are gaining vast acceptance to evaluate the relevant properties of drugs in the preclinical stage. The development of software programs and in silico models is further promoting the implementation of ADMET studies. Thus, the increasing need for drug-development ADME testing boosts the pharma ADMET testing market .

Middle East & Africa Pharma ADMET Testing Market Revenue and Forecast to 2028 (US$ Million)

Middle East & Africa Pharma ADMET Testing Market Segmentation

The Middle East & Africa pharma ADMET testing market is segmented by testing type, technology, application, and country. Based on testing type, the market is segmented into in vivo ADMET testing, in vitro ADMET testing, and in silico ADMET testing. The in vivo ADMET testing segment is dominating the market in 2022. Based on technology, the market is segmented into cell culture, high throughput, molecular imaging, and OMICS technology. The cell culture segment is dominating the market in 2022. Based on application, the market is segmented into systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others. The systemic toxicity segment is dominating the market in 2022. Based on country, the market is segmented intoSouth Africa, Saudi Arabia, the UAE, and the Rest of the Middle East & Africa. Further, South Africa dominated the market in 2022.

A few key players dominating the Middle East & Africa pharma ADMET testing market are Agilent Technologies, Inc.; Bio-Rad Laboratories, Inc.; Biovia (Dassault Systèmes); Charles River Laboratories; IQVIA Inc.; MERCK KGaA; Promega Corporation; and Wuxi AppTec.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Pharma ADMET Testing Market – By Testing Type
1.3.2 MEA Pharma ADMET Testing Market – By Technology
1.3.3 MEA Pharma ADMET Testing Market – By Application
1.3.4 MEA Pharma ADMET Testing Market – By Country
2. MEA Pharma ADMET Testing Market– Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Pharma ADMET Testing Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 MEA – PEST Analysis
4.3 Expert Opinion
5. Pharma ADMET Testing Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 High Rate of Late-Stage Drug Failure
5.1.2 Increasing Number of Product Approvals and Launches
5.2 Market Restraints
5.2.1 High Cost of ADME Testing Studies
5.3 Market Opportunities
5.3.1 Automation and Advancements in ADME Testing
5.4 Future Trends
5.4.1 The Advent of High-Throughput Screening
5.5 Impact Analysis
6. Pharma ADMET Testing Market– MEA Analysis
6.1 MEA Pharma ADMET Testing Market Revenue Forecast and Analysis
7. MEA Pharma ADMET Testing Market– By Testing Type
7.1 Overview
7.2 MEA Pharma ADMET Testing Market, By Testing Type 2022 & 2028 (%)
7.3 In Vivo ADMET Testing
7.3.1 Overview
7.3.2 In Vivo ADMET Testing – Revenue and Forecast to 2028 (US$ Million)
7.4 In Vitro ADMET Testing
7.4.1 Overview
7.4.2 In Vitro ADMET Testing – Revenue and Forecast to 2028 (US$ Million)
7.5 In Silico ADMET Testing
7.5.1 Overview
7.5.2 In Silico ADMET Testing – Revenue and Forecast to 2028 (US$ Million)
8. MEA Pharma ADMET Testing Market– By Technology
8.1 Overview
8.2 MEA Pharma ADMET Testing Market, By Technology 2022 & 2028 (%)
8.3 Cell Culture
8.3.1 Overview
8.3.2 Cell Culture – Market Revenue and Forecast to 2028 (US$ Million)
8.4 High Throughput
8.4.1 Overview
8.4.2 High Throughput – Market Revenue and Forecast to 2028 (US$ Million)
8.5 Molecular Imaging
8.5.1 Overview
8.5.2 Molecular Imaging – Market Revenue and Forecast to 2028 (US$ Million)
8.6 OMICS Technology
8.6.1 Overview
8.6.2 OMICS Technology – Market Revenue and Forecast to 2028 (US$ Million)
9. MEA Pharma ADMET Testing Market– By Application
9.1 Overview
9.2 MEA Pharma ADMET Testing Market, By Application 2022 & 2028 (%)
9.3 Systemic Toxicity
9.3.1 Overview
9.3.2 Systemic Toxicity – Market Revenue and Forecasts to 2028 (US$ Million)
9.4 Renal Toxicity
9.4.1 Overview
9.4.2 Renal Toxicity – Market Revenue and Forecasts to 2028 (US$ Million)
9.5 Hepatotoxicity
9.5.1 Overview
9.5.2 Hepatotoxicity – Market Revenue And Forecasts to 2028 (US$ Million)
9.6 Neurotoxicity
9.6.1 Overview
9.6.2 Neurotoxicity – Market Revenue And Forecasts to 2028 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others – Revenue And Forecasts to 2028 (US$ Million)
10. MEA Pharma ADMET Testing Market– Country Analysis
10.1 MEA: Pharma ADMET Testing Market
10.1.1 Overview
10.1.2 MEA Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Country (%)
10.1.2.1 UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.1.1 Overview
10.1.2.1.2 UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.1.3 UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
10.1.2.1.4 UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Technology (US$ Million)
10.1.2.1.5 UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
10.1.2.2 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.2.1 Overview
10.1.2.2.2 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.2.3 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
10.1.2.2.4 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Technology (US$ Million)
10.1.2.2.5 Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
10.1.2.3 South Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.3.1 Overview
10.1.2.3.2 South Africa Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.3.3 South Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
10.1.2.3.4 South Africa: Metabolomics Market Revenue and Forecasts To 2028, By Technology (US$ Million)
10.1.2.3.5 South Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
10.1.2.4 Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.4.1 Overview
10.1.2.4.2 Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
10.1.2.4.3 Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
10.1.2.4.4 Rest of MEA: Metabolomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
10.1.2.4.5 Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
11. MEA Pharma ADMET Testing Market–Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 Charles River Laboratories
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 WuXi AppTec
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Promega Corporation
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Sigma-Aldrich (MERCK KGaA)
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Agilent Technologies, Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Biovia (Dassault Systèmes)
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Bio-Rad Laboratories, Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 IQVIA Inc.
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms

LIST OF TABLES

Table 1.             MEA Pharma ADMET Testing Market –Revenue and Forecast to 2028 (US$ Million)
Table 2.             UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
Table 3.             UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 4.             UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 5.             Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
Table 6.             Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 7.             Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 8.             South Africa Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
Table 9.             South Africa: Metabolomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 10.          South Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 11.          Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Testing Type (US$ Million)
Table 12.          Rest of MEA: Metabolomics Market Revenue and Forecasts to 2028, By Technology (US$ Million)
Table 13.          Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Application (US$ Million)
Table 14.          Organic Developments Done by Companies
Table 15.          Inorganic Developments Done by Companies
Table 16.          Glossary of Terms
 
 

LIST OF FIGURES

Figure 1.           MEA Pharma ADMET Testing Market Segmentation
Figure 2.           MEA Pharma ADMET Testing Market, By Country
Figure 3.           MEA Pharma ADMET Testing Market Overview
Figure 4.           In vivo ADMET Testing Segment Held Largest Share of Testing Type Segment in MEA Pharma ADMET Testing Market
Figure 5.           South Africa is Expected to Show Remarkable Growth During the Forecast Period
Figure 6.           MEA: PEST Analysis
Figure 7.           Expert Opinion
Figure 8.           MEA Pharma ADMET Testing Market Impact Analysis of Driver and Restraints
Figure 9.           MEA Pharma ADME Testing Market– Revenue Forecast and Analysis – 2022 – 2028
Figure 10.        MEA Pharma ADMET Testing Market, by Testing Type 2022 & 2028 (%)
Figure 11.        In Vivo ADMET Testing – Revenue and Forecasts to 2028 (US$ Million)
Figure 12.        In Vitro ADMET Testing – Revenue and Forecasts to 2028 (US$ Million)
Figure 13.        In Silico ADMET Testing – Revenue and Forecasts to 2028 (US$ Million)
Figure 14.        MEA Pharma ADMET Testing Market, by Technology 2022 & 2028 (%)
Figure 15.        Cell Culture – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 16.        High Throughput – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17.        Molecular Imaging – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18.        OMICS Technology – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19.        MEA Pharma ADMET Testing Market, by Application 2022 & 2028 (%)
Figure 20.        Systemic Toxicity – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21.        Renal Toxicity – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22.        Hepatotoxicity – Market Revenue And Forecasts to 2028 (US$ Million)
Figure 23.        Neurotoxicity – Market Revenue And Forecasts to 2028 (US$ Million)
Figure 24.        Others – Revenue And Forecasts to 2028 (US$ Million)
Figure 25.        MEA Pharma ADMET Testing Market Revenue Overview, by Country, 2022 (US$ Million)
Figure 26.        MEA Pharma ADMET Testing Market Revenue and Forecasts to 2028, By Country (%)
Figure 27.        UAE: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28.        Saudi Arabia: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29.        South Africa: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)
Figure 30.        Rest of MEA: Pharma ADMET Testing Market Revenue and Forecasts to 2028 (US$ Million)

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East & Africa pharma ADMET testing market.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa pharma ADMET testing market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the pharma ADMET testing market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

The List of Companies – Middle East & Africa Pharma ADMET Testing Market

● Agilent Technologies, Inc.
● Bio-Rad Laboratories, Inc.
● Biovia (Dassault Systèmes)
● Charles River Laboratories
● IQVIA Inc.
● MERCK KGaA
● Promega Corporation
● Wuxi AppTec